Persistence of Infliximab in Circulation for 7 Years?

Clin Chem. 2015 Nov;61(11):1420-1. doi: 10.1373/clinchem.2015.242024.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / blood
  • Adalimumab / immunology
  • Adalimumab / therapeutic use
  • Antirheumatic Agents / blood*
  • Antirheumatic Agents / immunology*
  • Antirheumatic Agents / therapeutic use
  • Humans
  • Infliximab / blood*
  • Infliximab / immunology*
  • Infliximab / therapeutic use
  • Male
  • Middle Aged
  • Spondylitis, Ankylosing / blood
  • Spondylitis, Ankylosing / drug therapy*
  • Spondylitis, Ankylosing / immunology
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab